Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors

Lead Program Being Tested In AML, Moving Into Other Cancers

business team working on financial data analysis
Wugen raised $36m in seed and series A funding as it worked toward its $172m series B round • Source: Alamy

More from Financing

More from Business